Novartis heart failure treatment serelaxin fails in pivotal study

ZURICH (Reuters) - Novartis' efforts to expand its heart treatment franchise beyond its flagship Entresto business suffered a blow when it announced on Wednesday its acute heart failure drug serelaxin had failed in a late-stage trial.